April 1, 2026: Lawsuits Involving Ozempic & Other GLP-1s Climb to Over 3,500 Ozempics manufacturer, Novo Nordisk, and one other GLP-1 company are facing about 3,546 lawsuits in an active, federally consolidated MDL filed by former patients and their loved ones
The Roles of Insulin-Like Growth Factors in Mesenchymal Stem Cell Niche
Insurance & Coverage Cosmetic treatments for melasma are typically not covered by insurance
Nevertheless, many of the large-scale cardiovascular trials have reported the effects of DPP-4 inhibitors on aspects of diabetic nephropathy, specifically changes in urinary protein excretion, in glomerular function over time, and in the risk of progression to end-stage renal disease [47, 48, 84]